Evidence map›Paper›PMID 31686882›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019

Effects Of Saffron Supplementation On Inflammation And Metabolic Responses In Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.

Fatemeh Ebrahimi, Amirhossein Sahebkar, Naheed Aryaeian, Naseh Pahlavani, Soudabeh Fallah, Nariman Moradi, Davoud Abbasi, Agha Fatemeh Hosseini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 10 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 10 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Impact ofNutrients · 2020
    Pooled it
  11. Trial
  12. Effect ofNutrients · 2024
    Trial
  13. Trial
  14. Adverse Events of Saffron (Health science reports · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fatemeh EbrahimiSkull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7812-3017
Amirhossein SahebkarHalal Research Center of IRI, FDA, Tehran, Iran.
Naheed AryaeianDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9662-8561
Naseh PahlavaniStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0001-7960-7267
Soudabeh FallahDepartment of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-7377-6577
Nariman MoradiDepartment of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Davoud AbbasiDepartment of Internal Medicine, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-8954-7827
Agha Fatemeh HosseiniDepartment of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRMashhad University of Medical Sciences · IRKurdistan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes (T2D) is accompanied by elevated inflammation, oxidative stress, hyperlipidemia and hyperglycemia which all contribute to cardiovascular disease pathogenesis. Saffron as a complementary medicine and source of antioxidants could play a role in alleviating diabetes and its complications. The aim of this study was to determine the effects of saffron supplementation as an adjunct therapy in T2D. PATIENTS AND

methodsThis randomized controlled trial included 80 T2D patients with a mean age of 54.1 years. Participants were randomly assigned into two groups to take either saffron tablets (100 mg/day; n=40) or placebo (n=40) for 12 weeks. Fasting blood samples were obtained at the beginning and after the intervention period to quantify glycemic factors, lipid profile, and biomarkers of inflammation and oxidative stress. Anthropometric indices and dietary intakes were also measured at baseline and at study end.

resultsCompared with placebo, saffron supplementation resulted in significant decreases in waist circumference (

conclusionOverall, 12 weeks of saffron supplementation in diabetic patients had beneficial effects on waist circumference and serum MDA levels. However, saffron did not influence other evaluated cardio metabolic risk markers in diabetic patients.

Indexed as

crocus sativusdiabetes mellitusdysglycemiainflammation mediatorslipid profiletype 2

Identifiers

PMID31686882
PMCPMC6798815
OpenAlexW2979785657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.